Decrease (-) Restore Default Increase (+)

Clinical Trials

Topic   Cancer - Gynecologic Cancer
Title   Evaluation of HbA1c in Oncology Patients Beginning Intravenous Treatment
Summary   The main purpose of this study is to identify the prevalence of diabetes, undiagnosed diabetes and pre-diabetes in cancer patients beginning intravenous therapy.
Description   Individuals with diabetes who develop cancer have a worse overall survival rate and are more likely to develop an infection or be hospitalized when compared to those without diabetes who develop cancer. Patients with diabetes and cancer who are receiving chemotherapy are also at risk for developing more issues with blood sugar levels. This study provides a baseline HbA1c and a repeat HbA1c at a specified interval.
IRB Number   18304
Inclusion/Notes   To be eligible for this study, patients must meet several criteria, including but not limited to the following: patients must be 18 years of age or older and can be newly diagnosed or have recurrent cancer who have not yet started treatment for their current diagnosis. Those who have begun intravenous therapy, are on oral cancer treatment, have received a blood transfusion within the past three months, or who have had their HbA1c checked within the past 90 days are not eligible.
Status   Open
Start Date   04/26/2018
Principal Name   Eva Chalas, MD
Contact Name   Christina Egan, RN
Email   Christina.Egan@nyulangone.org
Fax   516-663-1871
Current Trial Type   Prospective
Phone   516-663-1216
Alternate Phone   516-663-3115